Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers
'Transfer of these INDs to Tivic allows us to formally engage the FDA regarding Entolimod's regulatory pathway and enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-related conditions,' stated Tivic CEO, Jennifer Ernst. 'While the IND for advanced cancers allows exploration of Entolimod's anti-tumor activity, building on prior developments, we remain focused in the near-term on Entolimod's first indication--acute radiation syndrome.'
About Entolimod
Entolimod is a novel TLR5 agonist that triggers NF-kB signaling, activating antiapoptotic and cell protective mechanisms. Under the FDA's Animal Rule, Entolimod has been the subject of extensive trials for the treatment of acute radiation syndrome (ARS), and has demonstrated robust survival, enhanced GI tract recovery and improved hematopoiesis in animal models. Entolimod has been granted Fast Track Designation for ARS.
Tivic also holds the exclusive rights for Entolimod for the treatment of neutropenia and has the option to license additional indications, including lymphocyte exhaustion, immunosenescence, and chronic radiation syndrome.
About Tivic
Tivic's dual platform strategy utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system.
Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late-stage development.
Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: https://ir.tivichealth.com.
Forward-Looking Statements
This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; timing and success of clinical trials and study results; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; regulatory requirements and pathways for approval; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors,' as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Meta Platforms, Inc. (META) CEO Mark Zuckerberg Is 'Unbelievable,' Says Jim Cramer
We recently published . Meta Platforms, Inc. (NASDAQ:META) is one of the stocks Jim Cramer recently discussed. Meta Platforms, Inc. (NASDAQ:META) is the largest social media company in the world. Its shares have gained 28% year-to-date on the back of strong advertisement performance and aggressive AI capital expenditure. Cramer is a fan of the firm's smart glasses, and he also believes that Meta Platforms, Inc. (NASDAQ:META) needs to reshape its communications about AI capital expenditure. He heaped praise on the glasses in his latest comments about the firm: 'But I love our tech so much. I just think our tech is really, I mean our tech is equivalent of you know like Zuckerberg. Meta. I mean he's unbelievable. . .I love the sunglasses, I'm bringing them on my trip. . . they, well you can look at a plant and say what is that? What am I looking at? And it works. . . it tells you exactly what it is.' Bloomua / In a recent appearance, Cramer discussed Meta Platforms, Inc. (NASDAQ:META) in detail. Here is what he said: 'Next best, Meta Platforms. I'm agog at the numbers that Mark Zuckerberg's putting up. The most important one, not even talked about on Wall Street enough, 3.5 billion people use at least one Meta product each day. Come on, that's almost half the planet. That's insane. The company's printing money, which is why it can go into the equivalent of free agency and hire incredible talent. It doesn't even matter. You can't even see it in the margins. While we acknowledge the potential of META as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Wire
18 minutes ago
- Business Wire
AM Best Affirms Credit Ratings of Saudi Arabian Insurance Company B.S.C. (c)
LONDON--(BUSINESS WIRE)-- AM Best has affirmed the Financial Strength Rating of B+ (Good) and the Long-Term Issuer Credit Rating of 'bbb-' (Good) of Saudi Arabian Insurance Company B.S.C. (c) (Damana) (Bahrain). The outlook of these Credit Ratings (ratings) is stable. The ratings reflect Damana's balance sheet strength, which AM Best assesses as very strong, as well as its marginal operating performance, limited business profile and marginal enterprise risk management. The ratings also factor in the neutral impact from Damana's ultimate parent, Mawarid Holding Company. Damana's balance sheet strength assessment is underpinned by its risk-adjusted capitalisation, which was at the very strong level as at year-end 2023, as measured by Best's Capital Adequacy Ratio (BCAR). AM Best expects BCAR scores to have recovered substantially to the strongest level in 2024, and year-to-date 2025, following the disposal of a large equity holding. Damana's investment portfolio is now largely conservative and consists mostly of cash and deposits. An offsetting factor to the assessment is the company's reliance on reinsurance for high-value risks, which is a common trait in the region; however, credit risk is minimised by a panel of sound credit quality. Damana's operating performance is assessed as marginal. The company has struggled with negative underwriting results for several years due to high expenses arising from its operating model and substantially reduced business scale. Loss ratios have also been affected by material events, such as the COVID-19 pandemic and the 2024 Dubai floods. Year-on-year improvements in the expense ratio have led to reductions in combined ratios from their peak of 148% in 2021, though underwriting operations remain unprofitable. Over the medium term and as the business continues to grow into its expense base, underwriting results are expected to trend towards profitability. Investment returns supplement performance, with Damana generating solid returns from its conservatively invested portfolio. Damana has seen business volumes steadily increase year-on-year since it suffered a reduction of revenues in 2021, following regulatory restrictions imposed by the Central Bank of Bahrain on the company's operations within that country. AM Best expects this trend in revenue growth to continue into the next few years, supported by Damana's renewed focus on new lines of business beyond its core lines of motor and medical. This strategy does expose Damana to execution risk given the challenging and competitive conditions in its core markets of Bahrain, the United Arab Emirates, Oman and Kuwait. This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.
Business Wire
18 minutes ago
- Business Wire
Nordson EFD Completes Eighth Job Shadowing Program with Polaris MEP
EAST PROVIDENCE, R.I.--(BUSINESS WIRE)-- Nordson EFD, a Nordson company (NASDAQ: NDSN), announced today it has completed its eighth year of support for the "Fast Track to Advanced Manufacturing" job shadowing program. Hosted by Polaris MEP and the Community College of Rhode Island (CCRI), this is a community-based program in its second year of support for the Jane Addams Resource Corporation (JARC-RI) training center in Providence, RI. The initiative aims to prepare individuals for careers in advanced manufacturing, with job shadowing being a key component of the hands-on experience in workforce training. Nordson EFD has been involved in local internships, facility tours, and hiring local Rhode Island students with the required technical skills for machining and other production jobs. The company partners with Fortune 500 companies and start-ups to solve the many challenges in assembly production with engineered dispensing technology. Polaris-CCRI Internship at Nordson EFD provides job shadowing opportunities and hands-on experience in workforce training. Share According to Polaris MEP, the Rhode Island manufacturing industry is experiencing a skills gap that translates to more available jobs than there are qualified workers. They estimate 3.5 million new skilled manufacturing jobs will be created in the next decade. "Fast Track to CNC Manufacturing" is a full-time 19-week program that introduces the fundamentals of manufacturing, safety, precision measurement and blueprint reading. Nordson EFD hosted 2 trainees from the last cohort as job shadow interns for three days a week, which adds a valuable applied learning component to the students' classroom and workshop education. Nordson EFD's precision fluid dispensing systems are manufactured at its East Providence, RI facility and utilized by various industries including medical device, electronics, and more. "My job shadow experience at Nordson EFD was a pleasant one,' stated Kudirat Aiyedun. 'I worked with engaging employees on the manufacturing floor who were all helpful and friendly. Some employees also helped me with ideas and training for my final project, which was Solid Works - ENGR 1030. I was instructed on how to read blueprints and operation sheets, as well as the use of a height gage, a micrometer and calipers. I was also taught how to set up a CNC milling machine during my internship. I enjoyed my time at Nordson EFD." "Nordson EFD has been an important employer partner since the inception of the program. They've opened their doors to our trainees, giving them hands on experience through job-shadowing opportunities,' states Aarin B. Clemons, Workforce Manager at Polaris MEP. 'We were among the first companies in Rhode Island to sign up with Polaris MEP to host and hire students participating in this mentorship program that prepares individuals for entry-level positions such as machinists/toolmakers and CNC operators,' states Scott Menko, Director of Operations, Nordson EFD. 'Job shadowing with industry professionals builds skills through practical learning, as students observe how tasks are performed in a real-world manufacturing environment. The networking aspect of the experience gives employers the opportunity to meet and nurture fresh talent with the potential to be hired after graduation.' About Nordson EFD Nordson EFD designs and manufactures precision fluid dispensing systems for benchtop assembly processes and automated assembly lines. By enabling manufacturers to accurately and consistently apply the same amount of assembly fluid to every part, EFD helps customers improve process control and throughput. In addition to producing high-quality fluid packaging syringe and cartridge systems, the company is also a leading formulator of specialty solder pastes for dispensing and printing applications. Nordson EFD is at the forefront of introducing Industry 4.0 efficiencies to the micro-dispensing marketplace, adding a new level of control and connectivity to its micro-dispensing solutions. Serving a wide variety of industries for more than 60 years, Nordson EFD has offices, application laboratories and technical support staff in 30 countries worldwide. To learn more, visit and follow us at About Nordson Corporation Nordson engineers, manufactures, and markets differentiated products and systems used for dispensing and processing adhesives, coatings, polymers, sealants and biomaterials; and for managing fluids, testing and inspecting for quality, treating surfaces and curing. These products are supported with extensive application expertise and direct global sales and service. We serve a wide variety of consumer non-durable, consumer durable and technology end markets including packaging, nonwovens, electronics, medical, appliances, energy, transportation, building and construction, and general product assembly and finishing. Founded in 1954 and headquartered in Westlake, Ohio, the company has operations and support offices in more than 30 countries. Visit Nordson on the web at
